- Home
- NVT vs MRNA Comparison
NVT vs MRNA Comparison
Compare NVT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVT | MRNA |
|---|---|---|
| Founded | 1903 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1B | 9.3B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NVT | MRNA |
|---|---|---|
| Price | $107.66 | $27.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 13 |
| Target Price | ★ $107.58 | $33.91 |
| AVG Volume (30 Days) | 2.2M | ★ 9.9M |
| Earning Date | 10-31-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 6.36 | N/A |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $3,578,600,000.00 | $2,232,000,000.00 |
| Revenue This Year | $28.70 | N/A |
| Revenue Next Year | $14.60 | $0.77 |
| P/E Ratio | $60.23 | ★ N/A |
| Revenue Growth | ★ 21.54 | N/A |
| 52 Week Low | $41.71 | $22.28 |
| 52 Week High | $117.52 | $48.92 |
Technical Indicators
Market Signals| Indicator | NVT | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 60.85 |
| Support Level | $102.25 | $23.92 |
| Resistance Level | $108.89 | $26.00 |
| Average True Range (ATR) | 3.74 | 1.29 |
| MACD | -0.01 | 0.32 |
| Stochastic Oscillator | 76.57 | 99.82 |
Price Performance
Historical ComparisonAbout NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.